Tiantian Wu

1PUBLICATIONS
0CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (1)

|Nov 25, 2023
Comparison of Efficacy and Safety of Anti-Programmed Cell Death-1 Antibody Plus Lenvatinib and Chemotherapy as First-Line Therapy for Patients with Stage IV Gallbladder Cancer: A Real-World Study in a Chinese Population.

Tiantian Wu, Changsheng Pu, Qiang Wang

Pageof 1

Frequent Collaborators